{"id":"W2995949931","doi":"10.1016/j.ygyno.2019.12.002","title":"EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Internal medicine; Discontinuation; Adverse effect; Sorafenib; Gastroenterology; Randomized controlled trial; Combination therapy; Surgery; Hepatocellular carcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255896,0.002227929,0.003329147,0.0006289104,0.0003901329,0.001054389,0.00120144,0.001958857,0.01076049],"category_scores_gemma":[0.001261597,0.0008675886,0.00163211,0.0005315978,0.001075286,0.001245659,0.0003891586,0.003990618,0.001657361],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006798805,"about_ca_system_score_gemma":0.001102655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00104579,"about_ca_topic_score_gemma":0.00216947,"domain_scores_codex":[0.9996793,0.0001495627,0.00002101237,0.00007337576,0.00002371219,0.00005303927],"domain_scores_gemma":[0.9995731,0.0001025374,0.00008939185,0.00002761506,0.00002582246,0.000181567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9702877,0.007295471,0.0002461456,0.001009378,0.000955498,0.00004183555,0.00002601077,0.000302654,0.003741532,0.0001615479,0.0014222,0.01450994],"study_design_scores_gemma":[0.9684692,0.02976134,0.0005031229,0.00001847527,0.0002209054,0.00002288993,0.000009603281,0.0002120016,0.0002366631,0.00005777353,0.0004795486,0.000008460936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9626692,0.01130426,0.002081496,0.001878151,0.001747178,0.007963077,0.003992948,0.0007187412,0.007644885],"genre_scores_gemma":[0.958086,0.007934179,0.004504544,0.003759819,0.001030342,0.008413585,0.004456981,0.00009207935,0.01172252],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01076049,"threshold_uncertainty_score":0.03599739,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02421069103510945,"score_gpt":0.3185982818749869,"score_spread":0.2943875908398774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}